Critical Comparison: Aptose Biosciences (NASDAQ:APTO) & JATT Acquisition (NYSE:JATT)

JATT Acquisition (NYSE:JATT) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Profitability

This table compares JATT Acquisition and Aptose Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Aptose Biosciences	N/A	-5,683.22%	-300.44%

Valuation and Earnings

This table compares JATT Acquisition and Aptose Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85 million	N/A	N/A
Aptose Biosciences	N/A	N/A	-$51.21 million	($89.19)	-0.04

Institutional & Insider Ownership

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 1.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for JATT Acquisition and Aptose Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0	0	0	0	0.00
Aptose Biosciences	0	0	3	1	3.25

Aptose Biosciences has a consensus price target of $130.00, indicating a potential upside of 3,330.08%. Given Aptose Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than JATT Acquisition.

Summary

JATT Acquisition beats Aptose Biosciences on 5 of the 9 factors compared between the two stocks.

About JATT Acquisition

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.